96 Tests PN: B112503


45x Ab-conjugated beads (S4P11 - Human MDC Ab-bead). PN: B112503A. One vial containing 100 µL of anti-Human MDC conjugated to AimPlex Bead S4P11.

25x Biotin-detection Ab (Human MDC Biotin-dAb). PN: B112503B. One vial containing 100 µL of biotinylated anti-Human MDC.

Lyophilized Standard Mix-Human Group 6, Panel B, 12-Plex. PN: HG62013. One vial containing lyophilized recombinant Eotaxin-2, IGFBP-1, IGFBP-7, MCP-4, MDC, MIP-1δ, MIP-3α, MIP-3β, IL-6Rα, IL-1RII, Gp130, and TNFRII. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying human CCL22/SCYA22/MDC. Can be multiplexed with other analytes in Human Group 6.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 5 pg/mL

  • Quantitation range:

  • LLOQ: < 10 pg/mL

  • ULOQ: > 2,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 6: Negligible

  • Sample volume: 15 µL/test


Chemokine (C-C Motif) Ligand 22, also known as Small Inducible Cytokine Subfamily A (Cys-Cys) 22 (SYCA22) and macrophage-derived chemokine (MDC), is a cytokine, that in humans, is secreted by dendritic cells and macrophages, and elicits its effects on its target cells by interacting with cell surface chemokine receptors such as CCR4. CCL22 displays chemotactic activity for monocytes, dendritic cells, natural killer cells and for chronically activated T lymphocytes. It also displays a mild activity for primary activated T lymphocytes and has no activity for neutrophils, eosinophils and resting T lymphocytes. Diseases associated with CCL22 include atopic keratoconjunctivitis and mycosis fungoides.


  1. Godiska R, Chantry D, Raport CJ, Sozzani S, Allavena P, Leviten D, Mantovani A, Gray PW (Jun 1997). "Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells". J Exp Med 185 (9): 1595–604. doi:10.1084/jem.185.9.1595. PMC 2196293. PMID 9151897.

  2. Nomiyama H, Imai T, Kusuda J, Miura R, Callen DF, Yoshie O (Oct 1998). "Human chemokines fractalkine (SCYD1), MDC (SCYA22) and TARC (SCYA17) are clustered on chromosome 16q13". Cytogenet Cell Genet 81 (1): 10–1. doi:10.1159/000015000. PMID 9691168.

  3. Vulcano M, Albanesi C, Stoppacciaro A, Bagnati R, D'Amico G, Struyf S, Transidico P, Bonecchi R, Del Prete A, Allavena P, Ruco LP, Chiabrando C, Girolomoni G, Mantovani A, Sozzani S (2001). "Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo". Eur. J. Immunol. 31 (3): 812–22. doi:10.1002/1521-4141(200103)31:3<812::AID-IMMU812>3.0.CO;2-L. PMID 11241286